Ignet
v2.0 Sign In

Gene Information

Gene symbol: BRD4

Gene name: bromodomain containing 4

HGNC ID: 13575

Synonyms: HUNKI, MCAP, CAP, HUNK1

Related Genes

# Gene Symbol Number of hits
1 BRPF1 1 hits
2 PARP1 1 hits
3 TIPARP 1 hits

Related Sentences

# PMID Sentence
1 34813314 Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
2 34813314 Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
3 34813314 Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
4 34813314 Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
5 34813314 Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation.
6 34813314 Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation.
7 34813314 Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation.
8 34813314 Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation.
9 34813314 Inducing the deficiency of homologous recombination (HR) repair is an effective way to broaden the indication of PARP1/2 inhibitor for more patients with pancreatic cancer.
10 34813314 Inducing the deficiency of homologous recombination (HR) repair is an effective way to broaden the indication of PARP1/2 inhibitor for more patients with pancreatic cancer.
11 34813314 Inducing the deficiency of homologous recombination (HR) repair is an effective way to broaden the indication of PARP1/2 inhibitor for more patients with pancreatic cancer.
12 34813314 Inducing the deficiency of homologous recombination (HR) repair is an effective way to broaden the indication of PARP1/2 inhibitor for more patients with pancreatic cancer.
13 34813314 Bromodomain-containing protein 4 (BRD4) repression has been reported to elevate HR deficiency.
14 34813314 Bromodomain-containing protein 4 (BRD4) repression has been reported to elevate HR deficiency.
15 34813314 Bromodomain-containing protein 4 (BRD4) repression has been reported to elevate HR deficiency.
16 34813314 Bromodomain-containing protein 4 (BRD4) repression has been reported to elevate HR deficiency.
17 34813314 Therefore, we designed, synthetized, and optimized a dual PARP/BRD4 inhibitor <b>III</b>-<b>16</b>, with a completely new structure and high selectivity against PARP1/2 and BRD4.
18 34813314 Therefore, we designed, synthetized, and optimized a dual PARP/BRD4 inhibitor <b>III</b>-<b>16</b>, with a completely new structure and high selectivity against PARP1/2 and BRD4.
19 34813314 Therefore, we designed, synthetized, and optimized a dual PARP/BRD4 inhibitor <b>III</b>-<b>16</b>, with a completely new structure and high selectivity against PARP1/2 and BRD4.
20 34813314 Therefore, we designed, synthetized, and optimized a dual PARP/BRD4 inhibitor <b>III</b>-<b>16</b>, with a completely new structure and high selectivity against PARP1/2 and BRD4.
21 34813314 The advantages of <b>III</b>-<b>16</b> over Olaparib suggest that dual PARP/BRD4 inhibitors are novel and promising agents for the treatment of advanced pancreatic cancer.
22 34813314 The advantages of <b>III</b>-<b>16</b> over Olaparib suggest that dual PARP/BRD4 inhibitors are novel and promising agents for the treatment of advanced pancreatic cancer.
23 34813314 The advantages of <b>III</b>-<b>16</b> over Olaparib suggest that dual PARP/BRD4 inhibitors are novel and promising agents for the treatment of advanced pancreatic cancer.
24 34813314 The advantages of <b>III</b>-<b>16</b> over Olaparib suggest that dual PARP/BRD4 inhibitors are novel and promising agents for the treatment of advanced pancreatic cancer.